These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

918 related items for PubMed ID: 19355805

  • 1. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P.
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [Abstract] [Full Text] [Related]

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ, Watson KE, Talbert RL.
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G, Maggioni AP.
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [Abstract] [Full Text] [Related]

  • 4. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL, Blazing MA, Saxena S, Guyton JR.
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [Abstract] [Full Text] [Related]

  • 5. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 6. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
    Schima SM, Maciejewski SR, Hilleman DE, Williams MA, Mohiuddin SM.
    Expert Opin Pharmacother; 2010 Apr 22; 11(5):731-8. PubMed ID: 20210682
    [Abstract] [Full Text] [Related]

  • 7. Treatment of high-risk older persons with lipid-lowering drug therapy.
    Aronow WS.
    Am J Ther; 2008 Apr 22; 15(2):102-7. PubMed ID: 18356628
    [Abstract] [Full Text] [Related]

  • 8. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S.
    Clin Ther; 2008 Feb 22; 30(2):294-306. PubMed ID: 18343268
    [Abstract] [Full Text] [Related]

  • 9. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 22; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 10. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA, Koro CE, Chan W, Bowlin SJ, Sprecher DL.
    Clin Ther; 2006 Feb 22; 28(2):243-50. PubMed ID: 16678645
    [Abstract] [Full Text] [Related]

  • 11. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA.
    Atheroscler Suppl; 2005 Sep 22; 6(3):21-7. PubMed ID: 16054442
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy with statins and omega-3 fatty acids.
    Nambi V, Ballantyne CM.
    Am J Cardiol; 2006 Aug 21; 98(4A):34i-38i. PubMed ID: 16919515
    [Abstract] [Full Text] [Related]

  • 13. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH.
    Am J Cardiol; 2007 Feb 19; 99(4A):133B-140B. PubMed ID: 17307065
    [Abstract] [Full Text] [Related]

  • 14. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 19; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 15. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug 19; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K.
    Indian Heart J; 2008 Aug 19; 60(3):215-22. PubMed ID: 19240310
    [Abstract] [Full Text] [Related]

  • 17. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA.
    Int J Clin Pract; 2011 Jan 19; 65(1):82-101. PubMed ID: 21105969
    [Abstract] [Full Text] [Related]

  • 18. Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Sarawate CA, Cziraky MJ, Stanek EJ, Willey VJ, Corbelli JC, Charland SL.
    Clin Ther; 2007 Jan 19; 29(1):196-209. PubMed ID: 17379061
    [Abstract] [Full Text] [Related]

  • 19. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH.
    J Cardiovasc Med (Hagerstown); 2010 Nov 19; 11(11):858-60. PubMed ID: 20686417
    [Abstract] [Full Text] [Related]

  • 20. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options.
    Stone NJ, Bilek S, Rosenbaum S.
    Am J Cardiol; 2005 Aug 22; 96(4A):53E-59E. PubMed ID: 16098845
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.